This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ARIAD To Host Analyst & Investor Day In New York City

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Analyst & Investor Day for research analysts and institutional investors will take place on Friday, October 19 at 8:00 a.m. (ET) in New York City. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, will host the event, which will include other key members of ARIAD executive leadership. The meeting will focus on ARIAD’s commercial plans for ponatinib and continued progress in its research and development programs. An expert physician specializing in the treatment of patients with lung cancer will be a featured speaker and discussant at the meeting.

A live webcast of the Analyst & Investor Day can be accessed by visiting the investor relations section of ARIAD’s website at A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for three weeks.


ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,798.07 +7.88 0.05%
S&P 500 1,980.90 +0.98 0.05%
NASDAQ 4,740.2840 -8.0770 -0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs